


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 **Claim 1.** (Currently amended) A compound having the formula:



2
3 wherein

4 R¹, R², R³ and R⁴ are members independently selected from H, substituted or
5 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or
6 unsubstituted heteroalkyl, substituted or unsubstituted aryl, ~~substituted or~~
7 ~~unsubstituted heteroaryl~~, OR⁸, NO₂, CN and halogen

8 wherein

9 R⁸ is a member selected from H, substituted or unsubstituted alkyl,
10 substituted or unsubstituted cycloalkyl and substituted or
11 unsubstituted aryl;

12 R⁵ is a member selected from H, substituted or unsubstituted alkyl, substituted or
13 unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl,
14 substituted or unsubstituted aryl, ~~substituted or unsubstituted heteroaryl~~,
15 CN and C(O)R⁹

16 wherein

17 R⁹ is a member selected from H, substituted or unsubstituted alkyl,
18 substituted or unsubstituted cycloalkyl, substituted or unsubstituted
19 heteroalkyl, NR¹⁰R¹¹ and OR¹¹

20 wherein

21 R^{10} is a member selected from H, substituted or unsubstituted
22 alkyl, substituted or unsubstituted cycloalkyl and OR^{12}
23 wherein
24 R^{12} is a member selected from H, substituted or
25 unsubstituted alkyl, substituted or unsubstituted
26 cycloalkyl and substituted or unsubstituted
27 heteroalkyl;
28 R^{11} is a member selected from H, $C(O)R^{13}$, substituted or
29 unsubstituted alkyl, substituted or unsubstituted cycloalkyl,
30 substituted or unsubstituted heteroalkyl, ~~substituted or~~
31 ~~unsubstituted heterocycloalkyl~~, and substituted or
32 unsubstituted aryl, ~~and wherein R^{10} and R^{11} , together with~~
33 ~~the nitrogen to which they are bound, are optionally joined~~
34 ~~to form a substituted or unsubstituted heterocycloalkyl ring~~
35 ~~system having from 3 to 7 members~~
36 wherein
37 R^{13} is a member selected from H, substituted or
38 unsubstituted alkyl, substituted or unsubstituted
39 cycloalkyl, substituted or unsubstituted heteroalkyl
40 and $NR^{14}R^{15}$
41 wherein
42 R^{14} and R^{15} are members independently selected
43 from H, substituted or unsubstituted alkyl
44 and substituted or unsubstituted heteroalkyl;
45 R^6 is a member selected from substituted alkyl, substituted and unsubstituted
46 heteroalkyl, CN, substituted or unsubstituted aryl, ~~substituted or~~
47 ~~unsubstituted heteroaryl~~ and $C(O)R^{16}$
48 wherein
49 R^{16} is a member selected from substituted or unsubstituted alkyl,
50 substituted or unsubstituted heteroalkyl, substituted or

51 unsubstituted aryl, ~~substituted or unsubstituted heteroaryl~~ NR¹⁷R¹⁸
52 and OR¹⁷


53 wherein

54 R¹⁷ and R¹⁸ are members independently selected from H,
55 substituted or unsubstituted alkyl, substituted or
56 unsubstituted heteroalkyl and substituted or unsubstituted
57 aryl, ~~and wherein R¹⁰ and R¹¹, together with the nitrogen to~~
58 ~~which they are bound, are optionally joined to form a~~
59 ~~heterocycloalkyl ring system having from 3 to 7 members;~~
60 R⁷ is a member selected from H, substituted or unsubstituted alkyl and substituted
61 or unsubstituted heteroalkyl.

1 **Claim 2.** (Previously presented) The compound according to claim 1, wherein at
2 least one of R¹⁰ and R¹¹ is substituted or unsubstituted C₁-C₆ alkyl.

1 **Claim 3.** (Currently amended) The compound according to claim 1, wherein R⁵ is a
2 member selected from substituted or unsubstituted C₁-C₆ alkyl, substituted or
3 unsubstituted C₁-C₆ heteroalkyl, and substituted or unsubstituted C₁-C₆ cycloalkyl and
4 ~~substituted or unsubstituted C₁-C₆ heterocycloalkyl.~~

1 **Claim 4.** (Previously presented) The compound according to claim 1, having the
2 formula:



1 **Claim 5.** (Cancelled).

1 **Claim 6.** (Previously presented) The compound according to claim 4, wherein R⁵ is
2 selected from substituted or unsubstituted C₁-C₆ alkyl and substituted or unsubstituted
3 C₁-C₆ cycloalkyl.

1 **Claim 7.** (Previously presented) The compound according to claim 4, wherein R³ is
2 halogen.

1 **Claim 8.** (Previously presented) A pharmaceutical formulation comprising a
2 compound according to claim 1 and a pharmaceutically acceptable carrier.

1 **Claim 9.** (Withdrawn) A method of inhibiting HIV in a cell, said method
2 comprising contacting said cell with an amount of a compound according to claim 1
3 sufficient to inhibit said HIV.

1 **Claim 10.** (Withdrawn) The method according to claim 9, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 11.** (Withdrawn) A method of inhibiting reverse transcriptase in a cell, said
2 method comprising contacting said cell with an amount of a compound according to
3 claim 1 sufficient to inhibit said reverse transcriptase.

1 **Claim 12.** (Withdrawn) The method according to claim 9, wherein said cell is in a
2 human.

1 **Claim 13.** (Withdrawn) The method according to claim 10, wherein said cell is in a
2 human.

1 **Claim 14.** (Withdrawn) A method of treating HIV infection in a human subject
2 comprising administering to said subject an amount of a compound according to claim 1,
3 sufficient to treat said HIV infection.

1 **Claim 15.** (Withdrawn) The method according to claim 14, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 16.** (Withdrawn) A method of providing prophylaxis against HIV infection
2 comprising administering a prophylactic amount of a compound according to claim 1 to a
3 person who is at risk of HIV infection.

1 **Claim 17.** (Withdrawn) The method according to claim 13, wherein said HIV is a
2 drug resistant mutant.

1 **Claim 18.** (Previously presented) The compound according to claim 1, wherein R⁶ is
2 a member selected from substituted and unsubstituted ether, substituted and unsubstituted
3 polyether, -CH₂OH, and -CH₂OC(O)CH₃.